Gilead Sciences, CRF commence Ranolazine trial to treat MACE
The trial will involve 2,600 patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI). Ranolazine is an extended-release tablet approved under
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.